Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 15, 2020

Long-term efficacy data shows MDMA is effective for treating PTSD

By Victoria Smith

The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and delayed-onset post-traumatic stress disorder (PTSD), currently in Phase III development in the US and Europe. Following positive Phase II trial data confirming that midoafetamine resulted in a significant reduction in PTSD symptoms, the FDA granted it a Breakthrough Therapy Designation in 2017.

Further results proceed to prove MDMA’s effectiveness in treating PTSD. Read more here.

Related Companies

Content from our partners
Clinical Evaluation Report template: a free resource for medical device manufacturers
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU